Evaluation of the Nephroprotective Effect of Finerenone (Kerendia®) in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Retrospective-Prospective Study

Authors

  • Jovana Škeljić Faculty of Medicine, University of Banja Luka Author
  • Đorđe Pilipović Faculty of Medicine, University of Banja Luka Author

Keywords:

Finerenone, type 2 diabetes mellitus, diabetic kidney disease, UACR, albuminuria

Abstract

Background: Diabetic Kidney Disease (DKD) is the primary cause of end-stage renal failure. Finerenone, a non-steroidal selective mineralocorticoid receptor antagonist (nMRA), showed potential nephroprotective properties in previous clinical trials.

Aim: The aim of this study was to evaluate the effectiveness, safety, and sex differences in response to finerenone therapy in patients with type 2 diabetes mellitus (T2DM) and DKD in a real-world clinical setting during a 6-month follow-up.

Material and Methods: A retrospective-prospective study followed a cohort of 25 patients (14 men, 11 women) with T2DM and DKD on stable RAAS blockers who started finerenone therapy (10-20 mg/day). Urinary albumin-to-creatinine ratio (UACR), eGFR, serum creatinine, potassium, and HbA1c were monitored at baseline (day 0) and after 6 months.

Results: Results showed a statistically significant (p=0.0096) reduction in urinary albumin after 6 months of therapy. A median UACR decrease of 48.1% was recorded, with 56.0% of patients (14/25) achieving a clinically significant response (UACR reduction over 30%). Sex differences showed that the treatment effect was more significant in women than in men: median UACR decrease of 75.4% in women (p=0.0186) versus 30.9% (p=0.583) in men. Finerenone caused no significant changes in kidney function markers: creatinine (p=0.183) and eGFR (p=0.323). Serum potassium averagely increased from 4.22 mmol/L to 4.60 mmol/L. Glycemic control (HbA1c) showed no significant changes.

Conclusion: Six-month use of finerenone is associated with reduced albuminuria, with a more pronounced effect and higher success rate in women than in men. The therapy maintained kidney function stability alongside an expected hemodynamic increase in creatinine and serum potassium, without significant changes in glycemic control (HbA1c). These findings indicate a favorable effectiveness and safety profile of finerenone in patients with T2DM and DKD in a real-world setting.

Published

2026-11-18

Issue

Section

Abstracts